John Fornadley, MD
Otolaryngology · Camp Hill, PANPI 1962505966
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,525 of the $26,853 with a category attached, or 76.4%. Optinose US, Inc. accounts for 88.5% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $9,296 and has fallen 57.1% since, to $3,992 in 2025. Among otolaryngology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 141 payments — averaging $190.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$24K
- Sanofi$2K
- Regeneron Healthcare Solutions, Inc.$496
- GSK$191
- Alk-abello, Inc$103
- Intersect ENT, Inc.$100
- plus $352 from 11 others
What the payments were for
- Consulting fees$3,18012%
- Speaking & faculty fees$20,52576%
- Travel & lodging$2041%
- Food & beverage$2,94411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 50 | $23,774 |
| Sanofi | 34 | $1,836 |
| Regeneron Healthcare Solutions, Inc. | 26 | $496 |
| GSK | 8 | $191 |
| Alk-abello, Inc | 7 | $103 |
| Intersect ENT, Inc. | 2 | $100 |
| Acclarent, Inc | 2 | $67 |
| Xoran Technologies LLC | 1 | $60 |
| Kaleo, Inc. | 3 | $59 |
| Integra Lifesciences Corporation | 1 | $44 |
| Merck | 1 | $21 |
| Regeneron | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Greer Laboratories, Inc. | 1 | $16 |
| Aerin Medical Inc. | 1 | $16 |
| Stryker | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,853 in reported general payments places this provider in the 95th percentile of 456 otolaryngology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 21 | $81,458 |
| Dupixent SyringeDupilumab | 14 | $54,305 |
| XhanceFluticasone Propionate | 21 | $17,244 |
| Mometasone Furoate | 23 | $1,422 |
| Fluticasone Propionate | 53 | $875 |
| Azelastine Hcl | 16 | $668 |
| Ipratropium Bromide | 19 | $520 |
| Mupirocin | 20 | $152 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $140 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 13 | $115 |
| Prednisone | 40 | $75 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $23,774 | $17,24421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 456 otolaryngology providers in Pennsylvania.
Other otolaryngology in Camp Hill
- Wesley Vander ArkCamp Hill$8K
- Nancy SnydermanPhiladelphia$4.5M
- David YenBethlehem$1.4M
- David KennedyPhiladelphia$603K
- Stella LeePittsburgh$438K
- James PalmerPhiladelphia$331K
- Ryan SooseSeven Fields$134K
- Mathew NagorskyPhiladelphia$95K
- Noam CohenPhiladelphia$76K
- Nithin AdappaPhiladelphia$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.